NYSE : IQV

IQVIA Holdings Inc.

$240.2 USD

$26.98 (12.65%)

Volume
2.4M
Average Volume
1.62M
Market Capitalization
$40.09B
P/E Ratio
29.54
Dividend Yield
0.00%
Price Target
$240.00
Year High
$247.72
Year Low
$154.50
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.71
Company Overview

NYSE

Ari Bousbib

Medical - Diagnostics & Research

Healthcare

IQV

93000

US

USD

https://www.iqvia.com

919 998 2000

46266C105

0001478242

Liquidity Metrics

0.41

0.71

0.71

0.22

0.00

Sales & Valuation

$16.31B

2.36

6.51

13.65

17.57

Profitability

$7.84

$1.36B

8.10%

9.47%

21.95%

4.60%

P/E Metrics

29.54

1.79

1.79

Analyst Price Target & Rating

$240.00

$250.00

$185.00

Neutral

3/5

44 Analysts

0.08%

Financial Health Scores

1.99

5/9

-$2.11B

$29.68B

$23.33B

$2.35B

Key Metrics (TTM)

$49.7B

2.99

14.12

0.75

22.46%

8.42%

3.86%

7.15%

$82.68

-22 days

Company Executives
Name Title
Eric Sherbet Executive Vice President, General Counsel & Secretary
Ari Bousbib Chief Executive Officer & Chairman
Duane Sachs Senior Vice President of Corporate Development
Jeffrey A. Spaeder Chief Medical & Scientific Officer
Kerri Joseph Senior VP of Investor Relations & Treasurer
Alistair Grenfell President of Commercial Solutions
James G. Berkshire Executive Vice President of Global Infrastructure & Operations
Michael J. Fedock Executive Vice President & Chief Financial Officer
W. Richard Staub President of Research & Development Solutions
Keriann Cherofsky Senior Vice President, Corporate Controller & Chief Accounting Officer
Poll Results

No votes yet today — be the first to share your view!

About IQVIA Holdings Inc. (NYSE:IQV) Stock

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers str ... ategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.

IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised

2026-07-28 11:41:12

IQVIA's Q2 earnings beat estimates as record R&D bookings, broad-based growth and stronger demand support a raised 2026 outlook.

IQVIA Holdings (IQV) Q2 Earnings and Revenues Beat Estimates

2026-07-28 09:16:07

IQVIA Holdings (IQV) came out with quarterly earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.02 per share. This compares to earnings of $2.81 per share a year ago.

IQVIA raises annual profit forecast on clinical research demand

2026-07-28 09:02:38

IQVIA Holdings raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong ​demand for its healthcare data and analytics services, ‌sending its shares up 11% before the bell.

Castleark Management LLC Makes New Investment in IQVIA Holdings Inc. $IQV

2026-07-28 04:09:58

Castleark Management LLC bought a new position in IQVIA Holdings Inc. (NYSE: IQV) in the undefined quarter, according to its most recent disclosure with the SEC. The firm bought 22,580 shares of the medical research company's stock, valued at approximately $3,851,000. Several other hedge funds and other institutional investors also recently modified their

IQVIA Holdings Inc. $IQV Shares Sold by Dai ichi Life Insurance Company Ltd

2026-07-27 03:56:08

Dai ichi Life Insurance Company Ltd decreased its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 34.1% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,723 shares of the medical research company's stock after selling 4,000 shares during the quarter. Dai ichi

Arrowstreet Capital Limited Partnership Raises Holdings in IQVIA Holdings Inc. $IQV

2026-07-25 03:43:24

Arrowstreet Capital Limited Partnership raised its stake in IQVIA Holdings Inc. (NYSE: IQV) by 3.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 992,190 shares of the medical research company's stock after acquiring an additional 30,051 shares during the quarter.

IQVIA Gears Up to Report Q2 Earnings: What's in the Offing?

2026-07-24 13:56:05

IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.

IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth

2026-07-21 11:00:46

IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Frequently Asked Questions

What is the current IQVIA Holdings Inc. (IQV) stock price?

IQVIA Holdings Inc.(NYSE:IQV) stock price is $240.2 in the last trading session. During the trading session, IQV stock reached the peak price of $247.7184 while $154.5 was the lowest point it dropped to. The percentage change in IQV stock occurred in the recent session was 12.65% while the dollar amount for the price change in IQV stock was $26.98.

IQV's industry and sector of operation?

The NYSE listed IQV is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of IQV?

Eric Sherbet | Executive Vice President, General Counsel & Secretary
Ari Bousbib | Chief Executive Officer & Chairman
Duane Sachs | Senior Vice President of Corporate Development
Jeffrey A. Spaeder | Chief Medical & Scientific Officer
Kerri Joseph | Senior VP of Investor Relations & Treasurer

How many employees does IQV have?

Number of IQV employees currently stands at 93000. IQV operates from 2400 Ellis Road, Durham, NC 27703, US.

Link for IQV official website?

Official Website of IQV is: https://www.iqvia.com

How do I contact IQV?

IQV could be contacted at phone #919 998 2000 and can also be accessed through its website. IQV operates from 2400 Ellis Road, Durham, NC 27703, US.

How many shares of IQV are traded daily?

The average number of IQV shares traded daily for last 3 months was 1.62M.

What is the market cap of IQV currently?

The market value of IQV currently stands at $40.09B with its latest stock price at $240.2